Dimensional Fund Advisors LP lifted its position in shares of Sierra Oncology Inc (NASDAQ:SRRA) by 38.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,039,548 shares of the biotechnology company’s stock after purchasing an additional 287,357 shares during the period. Dimensional Fund Advisors LP owned 1.40% of Sierra Oncology worth $3,077,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRRA. UBS Group AG bought a new position in shares of Sierra Oncology during the first quarter valued at about $111,000. Fred Alger Management Inc. purchased a new stake in Sierra Oncology during the second quarter worth about $246,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Sierra Oncology by 25.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,950 shares of the biotechnology company’s stock worth $305,000 after buying an additional 20,950 shares during the last quarter. Algert Global LLC increased its holdings in Sierra Oncology by 512.2% during the second quarter. Algert Global LLC now owns 143,991 shares of the biotechnology company’s stock worth $426,000 after buying an additional 120,471 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Sierra Oncology by 91,592.6% during the first quarter. JPMorgan Chase & Co. now owns 221,896 shares of the biotechnology company’s stock worth $459,000 after buying an additional 221,654 shares during the last quarter. 64.23% of the stock is currently owned by institutional investors.
NASDAQ SRRA opened at $1.78 on Friday. Sierra Oncology Inc has a 52-week low of $1.48 and a 52-week high of $4.09. The stock has a market cap of $131.40 million, a P/E ratio of -2.12 and a beta of 2.18.
SRRA has been the subject of a number of research analyst reports. ValuEngine downgraded shares of Sierra Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Zacks Investment Research upgraded shares of Sierra Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, September 25th.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Read More: Balance Sheet
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.